Securities Fraud Allegations Prompt ADMA Investors to Consider Class Action Lawsuit

ADMA Biologics, Inc. Investors Have Grounds for Class Action

In recent developments, investors of ADMA Biologics, Inc. (NASDAQ: ADMA) are being called upon to engage in a class action lawsuit following allegations of securities fraud. Led by Schall, Brown & Schwartz LLP, a prominent shareholder rights litigation firm, this initiative seeks to hold ADMA accountable for choices deemed deceptive under the law.

The allegations imply that ADMA made false and misleading statements within the realms of U.S. Securities Exchange regulations. Particularly, this case draws attention to violations pertaining to 3 10(b) and 20(a) of the Securities Exchange Act of 1934, along with Rule 10b-5 instituted by the U.S. Securities and Exchange Commission. The time frame under scrutiny spans from August 9, 2024, to March 25, 2026, culminating in a filing deadline of August 10, 2026.

Key Allegations

As outlined in the legal complaint, ADMA is accused of failing to adequately disclose several critical related party transactions, resulting in potential conflicts of interest. Additionally, it is asserted that the company resorted to channel stuffing—a practice that artificially inflates the amount of revenue reported—leading to misleading financial statements. Such actions generally compromise shareholders' trust and leave them exposed to unexpected losses when reality unwinds the deceptiveness of these reports.

ADMA's supposed failure to uphold appropriate internal controls further exacerbates the case. The firm's public declarations have been described as materially misleading by the plaintiffs, rendering the investors vulnerable to significant losses once the truth arose from the mist of these declarations.

According to Schall, Brown & Schwartz LLP, shareholders who acquired ADMA shares during the specified period are strongly encouraged to get in touch regarding potential lead plaintiff positions. Importantly, those who participate in the suit are assured that they do not necessarily need to be appointed as lead plaintiffs to gain recovery benefits.

The Importance of Acting

This class action is critical for individuals impacted by the alleged fraud. By joining forces, shareholders can better protect their rights and seek compensation for their losses. SBS is noted for its experience in securities class action cases and aims to aggressively advocate for each investor involved in the lawsuit.

For those considering this opportunity, the law firm offers a free consultation to discuss their rights and potential avenues for recovery. Interested shareholders can contact partners Brian Schall or David Schwartz directly via phone or through their firm’s website.

Conclusion

As the landscape of securities fraud continues to evolve, the ADMA Biologics incident underscores the necessity for transparency and accountability within publicly traded companies. Investors are encouraged to remain vigilant and proactive in their rights to protect their investments. For further details, please consider reaching out to SBS to ensure you are informed and prepared as this case unfolds.